| چکیده انگلیسی مقاله |
Background: Acute lymphoblastic leukemia (ALL) is the most common type of leukemia in children, often prevalent in children between the age of 2 and 6 years. However, it can lead to a loss of many years of life in these patients. Therefore, considering the importance of quality of life (QOL) for patients during treatment or after treatment discontinuation, and the extent of the therapeutic protocols, tools, and methods used to measure the QOL of children, we have undertaken a comprehensive review of the QOL of these patients. Methods: In designing a review of the outcomes, consultation with internal clinical experts was implemented first to identify relevant keywords and outcomes. We reviewed all English-language studies from 2000 to 2015 based on the Web of Science, PubMed, and Scopus databases. Results: 2621 studies were first identified in relevant electronic databases. However, only 10 studies met our inclusion criteria. Most of the selected studies used Health Utilities Index Mark 2 (HUI2) and 3 (HUI3) for assessing children's QOL. Some were interviewed by proxy, such as parents and even doctors and nurses involved in the treatment process. Most of the studies reported improvement of utility from 0.67% to 0.96% that in survivors varied from 0.71% to 0.94%. Conclusion: The results of this study illustrated that the treatment of patients with ALL in recent years has developed dramatically in different countries; and consequently, the QOL of these patients improved both during and after treatment. |
| نویسندگان مقاله |
| Hadi Hayati
School of Pharmacy, Lorestan University of Medical Sciences, Khorramabad, Iran
| Abbas Kebriaeezadeh
Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| Shekoufeh Nikfar
Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| Mohammad Ali Ehsani
Department of Pediatric Hematology and Oncology, School of Medicine AND Bahrami Hospital, Tehran University of Medical Sciences, Tehran, Iran
| Bahman Khosravi
Department of Health Management and Economics, School of Health, Tehran University of Medical Sciences, Tehran, Iran
| Mahdi Toroski
Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| Amin Hasanvand
School of Pharmacy, Lorestan University of Medical Sciences, Khorramabad, Iran
| Bereket Molla Tigabu
Department of Pharmacoeconomics and Pharmaceutical Management, School of Pharmacy, International Campus, Haramaya University, Haramaya, Ethiopia
|